You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma

Authors

  • Takashi Yoshida Department of Urology and Andrology, Kansai Medical University, Osaka, JapanGraduate School of Engineering, Tottori University, Tottori, JapanDepartment of Urology, Osaka Saiseikai-Noe Hospital, Osaka, JapanCorporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Takahiro Nakamoto Department of Urology and Andrology, Kansai Medical University, Osaka, JapanDepartment of Pathology, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Naho Atsumi Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, JapanDepartment of Pathology, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Chisato Ohe Department of Urology and Andrology, Kansai Medical University, Osaka, JapanDepartment of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Takeshi Sano Department of Urology and Andrology, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Yoshiki Yasukochi Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Koji Tsuta Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, JapanDepartment of Pathology, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles
  • Hidefumi Kinoshita Department of Urology and Andrology, Kansai Medical University, Osaka, Japan PubMed articlesGoogle scholar articles

Citation

Yoshida T, Nakamoto T, Atsumi N, et al
Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma
Journal for ImmunoTherapy of Cancer 2024;12:e009358. doi: 10.1136/jitc-2024-009358
Online issue publication 
July 23, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.